Search Results 11-20 of 17264 for TNF

1. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy - Mayo Clinic

   ... Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy ... TNF Therapy. Amended Protocol to Include a Lutikizumab Open-Label Sub-study ...

2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy - Mayo Clinic

   ... Tumor Necrosis Factor (TNF) therapy. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...

3. A Study Comparing the Safety of Tofacitinib versus Tumor Necrosis Factor Inhibitor in Patients with Rheumatoid Arthritis - Mayo Clinic

   The purpose of this post-marketing study is to compare the safety of tofacitinib versus tumor necrosis factor inhibitor with respect to major cardiovascular ...

4. Publications - Xia Zhou, M.B., Ph.D. - Mayo Clinic

   alpha -Klotho Promotes Cell Death and Suppresses Inflammation through TNF-Cellular Inhibitor of Apoptosis Protein 1 Signaling in Autosomal Dominant Polycystic ...

5. A Study To Assess Change In Disease Activity And Adverse Events Of Oral Upadacitinib In Adult And Adolescent Participants With Moderate To Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy - Mayo Clinic

   * Documented history of previous use of \>= 1 tumor necrosis factor (TNF) inhibitor for HS for at least 12 weeks and/or 1 approved non-anti-TNF biologic ...

6. A Study Of CNTO 136 (Sirukumab), A Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, In Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) - Mayo Clinic

   Have had anti-tumor necrosis factor (TNF)-alpha therapy and were unresponsive by 1 of the following 2 reasons: Lack of benefit to at least 1 anti-TNF-alpha ...

7. Inflammatory Bowel Disease Treatment And Response To Therapy - Mayo Clinic

   ... TNF-cycling among UC and CD patients with secondary loss of response or partial response to a prior anti-TNF. Participation eligibility. Participant ...

8. Mayo Clinic researchers to present study findings at American College of Gastroenterologists Annual Scientific Meeting

   Pardi. Anti-tumor necrosis factor (TNF) therapy linked to preeclampsia in women with inflammatory bowel disease. Women with inflammatory bowel disease have ...

9. Mayo Clinic researchers identify molecule linked to treatment-resistant inflammatory bowel disease

   Recently introduced medications target a pro-inflammatory molecule known as TNF ... She notes that the inflammation did not abate with TNF-alpha medication, ...

10. Upadacitinib (oral route) - Side effects & dosage - Mayo Clinic

    ... tumor necrosis factor [TNF] blockers) that did not work well or cannot be tolerated. Upadacitinib is also used to treat moderate to severe atopic dermatitis ...